Rapid coronavirus test speeds up access to urgent care and will free up beds ahead of winter

Rapid coronavirus test speeds up access to urgent care and will free up beds ahead of winter

  • decorative
    SAMBA II testing machines. Credit: Diagnostics for the Real World

Researchers say faster tests helped expedite access to life-saving treatments such as organ transplants – and might make all the difference later this year.

The first analysis of a new point-of-care 'nucleic acid test' for SARS-CoV-2 in a UK hospital setting shows these machines dramatically reduce time spent on COVID-19 ‘holding’ wards — allowing patients to be treated or discharged far quicker than with current lab testing procedures.

The rapid diagnostic capability of SAMBA II devices — an average of 2.6 hours compared with 26.4 hours for standard lab tests — led to an increased availability of ‘isolation rooms’ needed for infected patients, as well as fewer hospital bay closures.

University of Cambridge researchers behind the new study, currently a pre-print and awaiting peer-review, say that the time and hospital capacity spared by these devices will be “critical as we move towards autumn and winter”.

The SAMBA II machine was developed by a University spinout company, Diagnostics in the Real World, and deployed for trials in Addenbrooke’s Hospital, part of Cambridge University Hospitals NHS Foundation Trust (CUH). A donation from the businessman and philanthropist Sir Chris Hohn enabled Addenbrooke's Hospital to obtain the first 10 SAMBA II machines, with a further 10 machines to be funded by the CUH Trust.  "I'm delighted to have supported Dr Lee's important research and now help begin the rollout of this cutting-edge technology across the NHS", Hohn said.

“The backlog of routine operations and screenings as a result of the pandemic is a huge issue, and must be resolved ahead of winter, when the NHS will face even more pressure from other infections like norovirus and influenza,” said study lead author Professor Ravi Gupta.

Rapidly testing admissions for SARS-CoV-2 at the point of care is essential for reducing COVID-19 transmission in hospitals, speeding up access to urgent care and allowing safe discharge to care homes. Use of point-of-care testing would speed up the identification of patients for COVID-19 clinical trials, and receiving an experimental treatment a day earlier could make a clinical difference.

Professor Ravi Gupta

“Hospitals across the UK, as well as care homes and prisons, could benefit from SAMBA II devices,” said Gupta, from the Cambridge Institute of Therapeutic Immunology & Infectious Diseases (CITIID). “Given the technological capital of the UK we should not be falling so short on rapid point-of-care testing.”

Standard tests are sent for analysis in central laboratories, where backlogs can see delays of two days or more. SAMBA machines can produce a diagnosis in as little as 90 minutes.

Dr Helen Lee, CEO of Diagnostics in the Real World, developed the SAMBA II technology while at Cambridge’s Department of Haematology. The chemistry behind the machines has been used for on-the-spot HIV diagnostics across Africa.

The devices search for tiny traces of virus genetic code, and are extremely sensitive in the detection of active infections. Once nose and throat swabs have been loaded into a SAMBA machine, the process is fully automated, making them easy to use.

The initial ‘COVIDx’ clinical study led by Gupta at Addenbrooke’s with 149 participants found SAMBA II had 96.9% sensitivity (accurate identification of positive cases) and 99.1% specificity (accurate identification of negative cases) compared to the standard lab test. It was also around 24 hours faster. 

The success of the COVIDx study saw the hospital switch nearly all of its SARS-CoV-2 testing from the standard lab ‘RT-PCR’ tests over to the use of SAMBA II during May: an opportunity for a “real-world” comparison and its effect on hospital functioning.

Gupta and colleagues compared data from the electronic patient records of all those who had in-hospital tests done in the ten days before and then after the switch to SAMBA devices at CUH.

The researchers found that the average length of time patients had to spend on a COVID019 ‘holding’ ward before they could be discharged or progress with treatment almost halved: dropping from 58.5 hours to just 30 hours.

They also saw a fall in use of the single-occupancy ‘isolation’ rooms in which COVID-19 patients are ideally treated – from 30.8% to 21.2% after SAMBA’s introduction, as patients with symptoms were shown to be COVID-19 negative.

In fact, the researchers say the testing devices prevented 11 ward closures in the ten days after implementation. “Keeping surgical bays open means fewer cancelled operations, speeding up access to life-saving clinical intervention,” said Gupta.

The majority of those tested using SAMBA II during the first ten days of hospital-wide use were admissions to the Emergency Department (ED). The remainder included pre-op screenings and discharges to nursing homes.

The SAMBA II tests were “beneficial” for 76% of ED patients: expediting treatment or discharge, and allowing the release of examination rooms. The 24% without benefit was mainly due to triage or discharge before results were returned.

Some 96% of the SAMBA testing on pre-operative patients increased speed of “surgical intervention”, including kidney and liver transplants. The tests also allowed earlier discharge to nursing homes or into supported living in 79% of those cases, with the remainder delayed by “systematic issues” not tests themselves.

Dr Dami Collier, who coordinated and analysed COVIDx, said: “Our research demonstrates that point-of-care testing with SAMBA II machines is not only reliable, accurate and much faster, but that the diagnostic speed leads to significant real-world improvements for patient care and safety.”

CUH Medical Director, Dr Ashley Shaw, said: “Point of care testing has been hugely beneficial in enabling our clinical teams to make well-informed and timely decisions, keeping patients and staff as safe as possible throughout this difficult period.”

This work was supported by Wellcome, the Addenbrooke’s Charitable Trust, and the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre.

Adapted from an article originally published at the University's Research News page.

Get involved

You can support this research by making an online donation. If you would like to discuss further philanthropic opportunities, please contact Linda Hindmarsh.

Make a gift now

Make a gift now to support Cambridge COVID–19 Research Fund by credit or debit card, or set up a direct debit:

Give online

Or, find out about other ways to give.

Linda Hindmarsh

Senior Associate Director – School of Biological Sciences


+44 (0)1223 332288

This opportunity is part of

covid-19 virus image
Cambridge is working hard to ensure that the full strength of the University’s research powers and resources are used in the global fight against COVID-19.

Related stories

Philanthropic giving is at the heart of the success of the Collegiate University, enabling us to make discoveries that change the world and to ensure that our students receive an unrivalled education. Cambridge owes its world-leading excellence in research and teaching to the generosity of its supporters. Our history is synonymous with a history of far-sighted benefaction, and the same is as true today as it has ever been.

Philanthropic impact story
The COVID-19 pandemic will have a “profound” impact on philanthropy through forging more active collaboration and ensuring more equitable responses, Bill Gates said in an interview with Badr Jafar (Churchill College, 1997), founding patron of the Centre for Strategic Philanthropy at Cambridge Judge Business School.
Philanthropic impact story
A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK in late autumn or early next year, thanks to a £1.9million award from the UK government.
Philanthropic impact story
The University of Cambridge and Royal Papworth Hospital have secured £1.5million of funding as part of the national effort by UK immunologists to understand immune responses to SARS-CoV-2, the coronavirus that causes COVID-19.
Philanthropic impact story
Since the University of Cambridge launched its COVID-19 research fund in March, more than 250 donors have given generously to help in the fight against the novel coronavirus.
Philanthropic impact story
COVID-19 has dramatically altered our students’ university experience, radically changing the Cambridge they know and exacerbating any underlying disadvantages.
Philanthropic impact story
The second webinar in the series examined the numbers surrounding COVID-19 and the role that model-based knowledge can have on strategic and policy decisions.
Philanthropic impact story
Trinity alumna Professor Sadaf Farooqi is spearheading a Cambridge-China appeal to raise £5 million for PPE and alumnus Professor Yang Xia has donated and shipped facemasks from China to Cambridge. The equipment is intended to protect NHS and Social Care staff in the East of England.
Philanthropic impact story
AI assisted COVID-19 diagnostic and prognostic tool could improve resource allocation and patient outcomes

Giving opportunities

Philanthropic giving is at the heart of the success of the Collegiate University, enabling us to make discoveries that change the world and to ensure that our students receive an unrivalled education.

Research nurse from the NIHR Clinical Research Facility processing patient samples using SAMBA machines, Addenbrooke’s Hospital
The race is on to find a vaccine against the new COVID-19 coronavirus. Your support will make a difference.
Help support students at Cambridge experiencing hardship in this crisis and beyond.